Board Members

Anders Tullgren

Chairman of The Board

Anders has over 30 years of global experience in the pharmaceutical industry and has had senior leadership roles in the United States, Germany, France, the United Kingdom and the Nordic region. The latest role he left in 2017 was as President of the Intercontinental region of Bristol Myers Squibb with responsibility for over 30 countries, 5,000 employees and a turnover of over 20 billion. He is board member of Branding Science Ltd, UK, Biotoscana Invest S.A, Luxembourg and Farmalisto, Colombia. He holds a MSc in Pharmacy from Uppsala University.

Chairman of the Board since 2018.

Shares: 70,484

Warrants: 49,285

Independent in relation to the company and company management and major shareholders

Eva Nilsagård

Board Member

Eva Nilsagård holds a Executive MBA in Economics and a Bsc in accounting and finance from School of Business, Economics and Law in Gothenburg. Eva is currently interim CFO at OptiGroup AB and founder and CEO of Nilsagård Consulting AB which offers assignments as CEO and CFO. Previously, Eva has, among other things, served as CFO of Plastal Industry and Vitrolife, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development in, for example, Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the audit committee of Addlife, Bufab and Irras and board member of SEK (Swedish Export Credit Company). Eva has more than ten years of experience as a mentor for young female managers with high potential.

Board member since 2019

Shares: 4,000

Warrants: –

Independent in relation to the company and company management and major shareholders

Prof. Maris Hartmanis

Board Member

Maris is a seasoned industrial executive and leader with almost 30 years of CEO, senior R&D management and Board of Director experience from the international Life Science area. His experience stems from large organizations, as well as entrepreneurial start-ups. Most recently he was the CEO of two Swedish public pharmaceutical companies. Maris has a Ph.D. degree in Biochemistry from the Royal Institute of Technology in Stockholm, where he also is an Associate Professor.

Board member since 2015.

Shares: 12,139

Warrants: 2,250

Independent in relation to the company and company management and major shareholders

Karin Wingstrand

Board Member

Karin has a broad experience of the international pharmaceutical industry from senior positions within regulatory, pharmaceutical and analytical R&D, project leadership as well as clinical. Most recently Karin held the position of Global Head and Vice President of Clinical Development at AstraZeneca. Karin is also a board member of Integrum AB.

Board member since 2015.

Shares: 20,480

Warrants: 3,000

Independent in relation to the company and company management and major shareholders

Prof. Peter Edman

Board Member

Peter has an extensive experience in drug development from the pharmaceutical industry and has held a number of senior research leadership positions within Orexo, Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia. He has also held a position as Associate Professor at the Swedish Medical Product Agency. In addition, Peter has been Professor in Pharmaceutical Formulation and Adjunct Professor in Drug Delivery at the Faculty of Pharmacy, University of Uppsala. Peter is also a board member of Xintela AB.

Board member since 2015.

Shares: 12,747

Warrants: 2,250

Independent in relation to the company and company management and major shareholders

Giorgio Chirivi

Board Member

Giorgio is educated in finance and business administration at the University Luigi Bocconi in Italy and operates as Head of Mergers & Acquisitions at UBI Banca SpA. Giorgio also has a board assignment for Axxam SpA.

Board member since 2016.

Shares: 4,500

Warrants: 3,000

Independent in relation to the company and company management and major shareholders

Ivan Cohen-Tanugi

Board Member

Ivan Cohen-Tanugi holds a M.D. from Grenoble School of Medicine and master in business administration from H.E.C Business School. Ivan led the development of the Global Biosimilar platform & portfolio at Teva from R&D to BD and commercialization, then led the US commercial division (Teva Biologics & Specialty Products) focusing on Biosimilars, Branded Generics and Niche Specialties. More recently Ivan, amongst other things, was interim CEO and board member of Kuros Biosciences AG, CEO president of the board of Evevensys Biotechnology. Ivan has also held positions as Head Europe/International Business Unit Nephrology at AMGEN International and Vice President.

Board member since 2019

Shares: –

Warrants: –

Independent in relation to the company and company management and major shareholders